| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| ln Vitro |
BAL-1516 binds strongly to the NACHT domain of human NLRP3 with a Kd value of 14.2 nM, and its binding site is different from that of MCC950 [1]. BAL-1516 (10 μM; pre-incubated on ice for 30 min, then incubated with ATP at 25 °C for 68 min) does not inhibit the ATP hydrolysis activity of full-length human NLRP3 protein [1]. BAL-1516 binds to the NACHT domain of wild-type mouse NLRP3 with a Kd value of 200 nM, and its affinity is higher than that of the lead compound BAL-0028 [1]. BAL-1516 (incubated with doxycycline for 4 h, followed by stimulation with nigrain for 1 h) effectively inhibits the formation of nigrain-induced NLRP3 inflammasome ASC spots in HEK293T cells expressing human NLRP3, with an IC50 value of 14.5 nM [1]. BAL-1516 (0.256-4 μM; pre-incubated on ice for 30 minutes, followed by stimulation with nigra for 30 minutes) effectively inhibited the release of IL-1β and IL-18 from human induced pluripotent stem cell-derived microglia induced by LPS and nigra, with IC50 values of 11 nM and 9.0 nM, respectively [1].
|
|---|---|
| ln Vivo |
BAL-1516 (100 mg/kg; orally; single dose) showed excellent blood-brain barrier penetration and tissue stability in male CD-1 mice [1].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: Human iCell microglia Tested Concentrations: 0.256-4 μM Incubation Duration: Pre-incubation for 30 minutes, stimulation with nigra for 30 minutes (5 μg/mL, 2 hours) Experimental Results: Inhibited the release of IL-1β and IL-18 from human iPSC-derived microglia induced by LPS and nigra, with IC50 values of 11 nM and 9.0 nM, respectively, and did not cause significant cytotoxicity. |
| Animal Protocol |
Animal/Disease Models:CD-1 Mice (Male) [1]
Doses: 100 mg/kg Route of Administration: Oral; Single dose Experimental Results: 1 hour after administration, the average plasma concentration reached 1.5 × 10⁴ ng/mL, and the average brain tissue concentration reached 5 × 10³ ng/g. 6 hours after administration, the average plasma concentration reached 1 × 10³ ng/mL, and the average brain tissue concentration reached 1 × 10³ ng/g. 9 hours after administration, the average plasma concentration reached 1 × 10² ng/mL, and the average brain tissue concentration reached 1 × 10² ng/g. 12 hours after administration, the average plasma concentration reached 2 × 10² ng/mL, and the average brain tissue concentration reached 1 × 10² ng/g. 22 hours after administration, the average plasma concentration reached 10 ng/mL, and the brain tissue concentration was below the limit of quantitation. At 1 hour, 6 hours, 9 hours and 12 hours after administration, the brain tissue to plasma concentration ratio (Kp coefficient) was 0.3, 0.2, 0.1 and 0.1, respectively. |
| References |
| Molecular Formula |
C23H25N5O2S
|
|---|---|
| Molecular Weight |
435.54
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
CCOC1=CC(C(N([C@@H](C2=CN=C(C3=C2NN=C3)C)C)C)=O)=CC=C1C4=NC(C)=CS4
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2960 mL | 11.4800 mL | 22.9600 mL | |
| 5 mM | 0.4592 mL | 2.2960 mL | 4.5920 mL | |
| 10 mM | 0.2296 mL | 1.1480 mL | 2.2960 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
